Your browser doesn't support javascript.
loading
Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
Vanni, Tazio; Thomé, Beatriz C; Sparrow, Erin; Friede, Martin; Fox, Christopher B; Beckmann, Anna Marie; Huynh, Chuong; Mondini, Gabriella; Silveira, Daniela H; Viscondi, Juliana Y K; Braga, Patrícia Emilia; Silva, Anderson da; Salomão, Maria da Graça; Piorelli, Roberta O; Santos, Joane P; Gattás, Vera Lúcia; Lucchesi, Maria Beatriz B; Oliveira, Mayra M M de; Koike, Marcelo E; Kallas, Esper G; Campos, Lucia M A; Coelho, Eduardo B; Siqueira, Marilda A M; Garcia, Cristiana C; Miranda, Milene Dias; Paiva, Terezinha M; Timenetsky, Maria do Carmo S T; Adami, Eduardo A; Akamatsu, Milena A; Ho, Paulo Lee; Precioso, Alexander R.
Afiliação
  • Vanni T; Instituto Butantan, São Paulo, Brazil.
  • Thomé BC; Instituto Butantan, São Paulo, Brazil.
  • Sparrow E; World Health Organization, Geneva, Switzerland.
  • Friede M; World Health Organization, Geneva, Switzerland.
  • Fox CB; Infectious Disease Research Institute, Seattle, WA, United States of America.
  • Beckmann AM; Infectious Disease Research Institute, Seattle, WA, United States of America.
  • Huynh C; Biomedical Advanced Research and Development Authority, Washington, DC, United States of America.
  • Mondini G; Instituto Butantan, São Paulo, Brazil.
  • Silveira DH; Instituto Butantan, São Paulo, Brazil.
  • Viscondi JYK; Instituto Butantan, São Paulo, Brazil.
  • Braga PE; Instituto Butantan, São Paulo, Brazil.
  • Silva AD; Instituto Butantan, São Paulo, Brazil.
  • Salomão MDG; Instituto Butantan, São Paulo, Brazil.
  • Piorelli RO; Instituto Butantan, São Paulo, Brazil.
  • Santos JP; Instituto Butantan, São Paulo, Brazil.
  • Gattás VL; Instituto Butantan, São Paulo, Brazil.
  • Lucchesi MBB; Instituto Butantan, São Paulo, Brazil.
  • Oliveira MMM; Instituto Butantan, São Paulo, Brazil.
  • Koike ME; Instituto Butantan, São Paulo, Brazil.
  • Kallas EG; Clinics Hospital of the School of Medicine of University of São Paulo, São Paulo, Brazil.
  • Campos LMA; Child Institute of the Clinics Hospital of the School of Medicine of University of São Paulo, São Paulo, Brazil.
  • Coelho EB; Clinics Hospital of the Medical School of Ribeirão Preto of the University of São Paulo, Ribeirão Preto, Brazil.
  • Siqueira MAM; Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
  • Garcia CC; Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
  • Miranda MD; Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
  • Paiva TM; Adolfo Lutz Institute, São Paulo, Brazil.
  • Timenetsky MDCST; Adolfo Lutz Institute, São Paulo, Brazil.
  • Adami EA; Instituto Butantan, São Paulo, Brazil.
  • Akamatsu MA; Instituto Butantan, São Paulo, Brazil.
  • Ho PL; Instituto Butantan, São Paulo, Brazil.
  • Precioso AR; Instituto Butantan, São Paulo, Brazil.
PLoS One ; 17(10): e0274943, 2022.
Article em En | MEDLINE | ID: mdl-36256646
ABSTRACT
The emergence of potentially pandemic viruses has resulted in preparedness efforts to develop candidate vaccines and adjuvant formulations. We evaluated the dose-sparing effect and safety of two distinct squalene-based oil-in-water adjuvant emulsion formulations (IB160 and SE) with influenza A/H7N9 antigen. This phase I, randomized, double-blind, placebo-controlled, dose-finding trial (NCT03330899), enrolled 432 healthy volunteers aged 18 to 59. Participants were randomly allocated to 8 groups 1A) IB160 + 15µg H7N9, 1B) IB160 + 7.5µg H7N9, 1C) IB160 + 3.75µg H7N9, 2A) SE + 15µg H7N9, 2B) SE + 7.5µg H7N9, 2C) SE + 3.75µg H7N9, 3) unadjuvanted vaccine 15µg H7N9 and 4) placebo. Immunogenicity was evaluated through haemagglutination inhibition (HI) and microneutralization (MN) tests. Safety was evaluated by monitoring local and systemic, solicited and unsolicited adverse events (AE) and reactions (AR) 7 and 28 days after each study injection, respectively, whereas serious adverse events (SAE) were monitored up to 194 days post-second dose. A greater increase in antibody geometric mean titers (GMT) was observed in groups receiving adjuvanted vaccines. Vaccinees receiving IB160-adjuvanted formulations showed the greatest response in group 1B, which induced an HI GMT increase of 4.7 times, HI titers ≥40 in 45.2% of participants (MN titers ≥40 in 80.8%). Vaccinees receiving SE-adjuvanted vaccines showed the greatest response in group 2A, with an HI GMT increase of 2.5 times, HI titers ≥40 in 22.9% of participants (MN titers ≥40 in 65.7%). Frequencies of AE and AR were similar among groups. Pain at the administration site and headache were the most frequent local and systemic solicited ARs. The vaccine candidates were safe and the adjuvanted formulations have a potential dose-sparing effect on immunogenicity against influenza A/H7N9. The magnitude of this effect could be further explored.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / Subtipo H7N9 do Vírus da Influenza A Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / Subtipo H7N9 do Vírus da Influenza A Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil